PHVS News and Press, Pharvaris N.V.

2026-03-12 11:07:25 ET Shares of protease inhibitor concern KalVista Pharmaceuticals, Inc. ( KALV ) have moved up following FDA approval of its HAE therapy Ekterly. Since the July 2025 green light, the first oral on-demand treatment for HAE attacks has generated revenue of $49 m...

Data include a concurrent assessment of results collected from PGI and AMRA instruments, insights into clinically meaningful changes in HAE attack symptoms, and support for hierarchical ranking of RAPIDe-3 endpoints ZUG, Switzerland, March 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHV...

RAPIDe-3 met the primary and all 11 secondary efficacy endpoints with high statistical significance with deucrictibant achieving onset of symptom relief in 1.28 hours and complete symptom resolution in 11.95 hours, and confirming its potentially differentiated profile for the treatment of HAE att...

ZUG, Switzerland, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and ac...

Topline data from CHAPTER-3, a pivotal study of deucrictibant for prophylactic treatment of HAE attacks, anticipated in 3Q2026 Preparation of NDA dossier of deucrictibant for on-demand treatment of HAE attacks ongoing; timeline remains on-track for filing in 1H2026 Recruitment ongoing in CREAAT...

2026-01-06 11:59:13 ET More on the markets Jubilant Hopes For The U.S. Stock Market For 2026 U.S. Economy Expected To Cool In Q4, Based On Latest Nowcasts Housing Looks Like A Low-Risk Opportunity Now U.S. stocks continue climbing thanks to Nvidia, tech trade...

2025-12-03 20:06:29 ET Maxwell Skor from Morgan Stanley issued a price target of $41.00 for PHVS on 2025-12-04 00:12:06. The adjusted price target was set to $41.00. At the time of the announcement, PHVS was trading at $29.365. The overall price target consensus is at $4...

2025-12-03 19:15:03 ET Morgan Stanley analyst issues OVERWEIGHT recommendation for PHVS on December 4, 2025 12:12AM ET. The previous analyst recommendation was Overweight. PHVS was trading at $29.365 at issue of the analyst recommendation. The overall analyst consensus :...

2025-12-03 17:43:24 ET Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary Angioedema December 3, 2025 8:00 AM EST... Read the full article on Seeking Alpha For further details see: Pharvaris N.V. (PHVS) Discusses Toplin...

2025-12-03 16:06:30 ET from Leerink Partners issued a price target of $38.00 for PHVS on 2025-12-03 19:56:33. The adjusted price target was set to $38.00. At the time of the announcement, PHVS was trading at $29.365. The overall price target consensus is at $60.00 with h...